IRONWOOD PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Description as filed by funds: Election of Directors. To elect nine director nominees numbered 01 through 09 to serve for a one-year term extending until the 2025 annual meeting of stockholders and their successors are duly elected and qualified: Alexander Denner, Ph.D.

IRONWOOD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Alexander Denner, Ph.D.”): 125,450,072 for, 10,041,760 withheld, per its Form 8-K filed June 21, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The stockholders elected nine director nominees, each to serve on the board of directors of the Company for a one-year term extending until the 2024 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her death, resignation or removal, based …”
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 89 asset managers below reported 69,700,287 for, 2,333,295 withheld, 7,297 abstained.

Showing the 25 largest of 89 asset managers. See all 89 in the interactive database.

Description as filed by funds: Election of Directors. To elect nine director nominees numbered 01 through 09 to serve for a one-year term extending until the 2025 annual meeting of stockholders and their successors are duly elected and qualified: Andrew Dreyfus

IRONWOOD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Andrew Dreyfus”): 129,704,783 for, 5,787,049 withheld, per its Form 8-K filed June 21, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The stockholders elected nine director nominees, each to serve on the board of directors of the Company for a one-year term extending until the 2024 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her death, resignation or removal, based …”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 89 asset managers below reported 71,972,072 for, 61,510 withheld, 7,297 abstained.

Showing the 25 largest of 89 asset managers. See all 89 in the interactive database.

Description as filed by funds: Election of Directors. To elect nine director nominees numbered 01 through 09 to serve for a one-year term extending until the 2025 annual meeting of stockholders and their successors are duly elected and qualified: Catherine Moukheibir

IRONWOOD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Catherine Moukheibir”): 129,803,799 for, 5,688,033 withheld, per its Form 8-K filed June 21, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The stockholders elected nine director nominees, each to serve on the board of directors of the Company for a one-year term extending until the 2024 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her death, resignation or removal, based …”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 89 asset managers below reported 71,928,401 for, 108,463 withheld, 4,015 abstained.

Showing the 25 largest of 89 asset managers. See all 89 in the interactive database.

Description as filed by funds: Election of Directors. To elect nine director nominees numbered 01 through 09 to serve for a one-year term extending until the 2025 annual meeting of stockholders and their successors are duly elected and qualified: Jay Shepard

IRONWOOD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jay Shepard”): 133,672,033 for, 1,819,799 withheld, per its Form 8-K filed June 21, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The stockholders elected nine director nominees, each to serve on the board of directors of the Company for a one-year term extending until the 2024 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her death, resignation or removal, based …”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 89 asset managers below reported 71,975,354 for, 61,510 withheld, 4,015 abstained.

Showing the 25 largest of 89 asset managers. See all 89 in the interactive database.

Description as filed by funds: Election of Directors. To elect nine director nominees numbered 01 through 09 to serve for a one-year term extending until the 2025 annual meeting of stockholders and their successors are duly elected and qualified: Jon Duane

IRONWOOD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jon Duane”): 127,436,834 for, 8,054,998 withheld, per its Form 8-K filed June 21, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The stockholders elected nine director nominees, each to serve on the board of directors of the Company for a one-year term extending until the 2024 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her death, resignation or removal, based …”
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 89 asset managers below reported 71,646,693 for, 390,171 withheld, 4,015 abstained.

Showing the 25 largest of 89 asset managers. See all 89 in the interactive database.

Description as filed by funds: Election of Directors. To elect nine director nominees numbered 01 through 09 to serve for a one-year term extending until the 2025 annual meeting of stockholders and their successors are duly elected and qualified: Julie McHugh

IRONWOOD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Julie McHugh”): 124,822,215 for, 10,669,617 withheld, per its Form 8-K filed June 21, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The stockholders elected nine director nominees, each to serve on the board of directors of the Company for a one-year term extending until the 2024 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her death, resignation or removal, based …”
Support: 92% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 89 asset managers below reported 71,646,693 for, 390,171 withheld, 4,015 abstained.

Showing the 25 largest of 89 asset managers. See all 89 in the interactive database.

Description as filed by funds: Election of Directors. To elect nine director nominees numbered 01 through 09 to serve for a one-year term extending until the 2025 annual meeting of stockholders and their successors are duly elected and qualified: Mark Currie, Ph.D.

IRONWOOD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Mark Currie, Ph.D.”): 130,019,704 for, 5,472,128 withheld, per its Form 8-K filed June 21, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The stockholders elected nine director nominees, each to serve on the board of directors of the Company for a one-year term extending until the 2024 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her death, resignation or removal, based …”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 89 asset managers below reported 71,975,354 for, 61,510 withheld, 4,015 abstained.

Showing the 25 largest of 89 asset managers. See all 89 in the interactive database.

Description as filed by funds: Election of Directors. To elect nine director nominees numbered 01 through 09 to serve for a one-year term extending until the 2025 annual meeting of stockholders and their successors are duly elected and qualified: Marla Kessler

IRONWOOD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Marla Kessler”): 130,081,722 for, 5,410,110 withheld, per its Form 8-K filed June 21, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The stockholders elected nine director nominees, each to serve on the board of directors of the Company for a one-year term extending until the 2024 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her death, resignation or removal, based …”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 89 asset managers below reported 71,975,354 for, 61,510 withheld, 4,015 abstained.

Showing the 25 largest of 89 asset managers. See all 89 in the interactive database.

Description as filed by funds: Election of Directors. To elect nine director nominees numbered 01 through 09 to serve for a one-year term extending until the 2025 annual meeting of stockholders and their successors are duly elected and qualified: Thomas McCourt

IRONWOOD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Thomas McCourt”): 133,639,699 for, 1,852,133 withheld, per its Form 8-K filed June 21, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The stockholders elected nine director nominees, each to serve on the board of directors of the Company for a one-year term extending until the 2024 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her death, resignation or removal, based …”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 89 asset managers below reported 71,975,354 for, 61,510 withheld, 4,015 abstained.

Showing the 25 largest of 89 asset managers. See all 89 in the interactive database.

Description as filed by funds: Approval, by non-binding advisory vote, of the compensation paid to the named executive officers.

IRONWOOD PHARMACEUTICALS INC.’s own tally for this item (“2. On a non-binding advisory basis, the compensation paid to the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Meeting, based on the following votes”): 127,439,687 for, 7,953,508 against — passed, per its Form 8-K filed June 21, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders approved, on a non-binding advisory basis, the compensation paid to the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Meeting, based on the following votes:”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 92 managers: 71,256,192 for, 1,563,921 against, 34,334 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 215 managers: 60,849,759 for, 5,664,248 against, 1,441,029 withheld, 28,581 abstained, 2,989 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: Ratification of the selection of Ernst & Young LLP as Ironwood Pharmaceuticals, Inc.'s independent registered public accounting firm for 2024.

IRONWOOD PHARMACEUTICALS INC.’s own tally for this item (“3. The selection of Ernst & Young LLP as the Company's independent registered public accounting firm for 2024, based on the following votes”): 136,781,986 for, 6,305,538 against — passed, per its Form 8-K filed June 21, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for 2024, based on the following votes:”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 94 asset managers below reported 72,666,663 for, 153,922 against, 34,334 abstained.

Showing the 25 largest of 94 asset managers. See all 94 in the interactive database.